The global cutting balloons market was valued at USD 400.2 Million in 2022 and is expected to reach USD 725.9 Million by 2033. The drug-coated cutting balloons products with around 42.1% value share, have topped the global market within the product in 2022 and are expected to grow at a CAGR of close to 6.0% over the forecast period (2023 to 2033)
Key Market Attributes
| Market Size, 2022 | USD 400.2 Million |
|---|---|
| Market Size, 2023 | USD 421.2 Million |
| Market Size, 2033 | USD 725.9 Million |
| Value CAGR (2023 to 2033) | 5.6% |
The cutting balloons market refers to the medical devices used in minimally invasive procedures to treat arterial blockages. These balloons have small blades or microtomes attached to their surface, enabling precise cutting of plaque within arteries. The market is projected to experience substantial growth in the next decade due to rising cases of cardiovascular diseases and the increasing adoption of minimally invasive procedures.
Technological advancements and improved efficacy of cutting balloons are expected to drive demand. Additionally, the growing aging population and the focus on improving healthcare infrastructure worldwide will likely contribute to the market's expansion, addressing the rising need for effective vascular treatments.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for cutting balloons was around 2.3% of the overall USD 17.5 Billion of the global interventional cardiology devices market in 2022.
Semi Annual Market Update
| Particular | Value CAGR |
|---|---|
| H1 | 4.90% (2022 to 2032) |
| H2 | 6.22% (2022 to 2032) |
| H1 | 5.36% (2023 to 2033) |
| H2 | 5.82% (2023 to 2033) |
The cutting balloon market has witnessed significant growth from 2017 to 2022 due to its unique advantages in percutaneous coronary interventions. Unlike traditional methods, the cutting balloon reduces vessel stretch and injury by scoring the vessel longitudinally, leading to controlled disruption of atherosclerotic plaque. This innovative approach has garnered attention as it minimizes risks associated with vessel damage.
However, the market outlook for 2023 to 2033 indicates a continued upward trajectory due to growing awareness of its benefits. Coronary artery calcification poses challenges for conventional angioplasty, making cutting balloon angioplasty a preferred option. The device's microsurgical metal blades effectively incise calcifications during dilation, leading to better luminal gain and reduced risks of restenosis and stent thrombosis.
Clinical studies suggest that cutting balloon angioplasty demonstrates superiority over conventional methods in terms of acute luminal gain and reduced target vessel revascularization incidence. Despite concerns about the risk of artery lesion tear, advancements in technology and improved procedural techniques are expected to address such issues.
In conclusion, the cutting balloon market has evolved significantly, showcasing its efficacy in handling complex calcified artery lesions. The market is poised for continued growth in the coming years, driven by increased acceptance within the medical community and ongoing advancements in technology that mitigate potential complications.
Owed to the above factors, the global market is projected to grow at a CAGR of 5.6% in the forecasted period.
The provider of cutting balloons has significant opportunities in the field of coronary intervention. When dealing with patients suffering from acute coronary syndrome (ACS) and having dense blockages, there is a frequent need for preliminary widening before inserting stents. Utilizing cutting balloons (CBs) can yield superior immediate results compared to alternative scoring balloons, thereby minimizing the chances of particles breaking loose and causing complications downstream.
The innovative Wolverine cutting balloon has shown promising results in treating calcified coronary lesions, offering a potential solution to the challenges posed by calcification during angioplasty. Additionally, the study's focus on investigating the appropriate balloon-to-artery ratio (BAR) for CBs presents an opportunity to enhance procedural precision and reduce the risk of complications.
The adoption of cutting balloons in combination with drug-coated balloons (DCBs) for in-stent restenosis (ISR) lesions also opens avenues for improved patient outcomes. The study's findings suggest that combining cutting balloon angioplasty (CBA) with DCBs could lead to better results in lowering the recurrence of ISR. Moreover, the study's exploration of in-stent dilation in circumferential coronary calcifications using cutting balloons presents a breakthrough in addressing challenges associated with heavy coronary calcification during stent implantation.
These opportunities underscore the potential of cutting balloons to advance coronary intervention techniques, enhance procedural success rates, and ultimately improve patient care. The utilization of cutting balloons, particularly the innovative Wolverine model, demonstrates the service provider's commitment to delivering effective solutions for complex coronary conditions, making a significant impact in the field of interventional cardiology.
Principal Consultant
The demand for cutting balloons is influenced by several factors. Cost is a major barrier, as cutting balloons requires advanced technology and specialized training for medical professionals. Alternative treatments like traditional balloon angioplasty or stent placement are more cost-effective and less invasive. The risk of complications is another concern, as physicians and patients may opt for less risky options.
Cutting balloons are primarily used for specific cases involving calcified or tough lesions, potentially reducing their demand. Regulatory hurdles, lack of awareness among patients and healthcare providers, preference for drug-eluting stents, and inadequate healthcare infrastructure also contribute to the market's restraint. These factors collectively hinder the adoption of cutting balloons, impacting their market growth and adoption within the medical industry.
| Country | Value CAGR |
|---|---|
| United States | 5.4% |
| Germany | 4.8% |
| United Kingdom | 4.4% |
| Japan | 5.9% |
| China | 5.3% |
| India | 4.5% |
The United States occupied a 38.6% value share in the global market in 2022, and expenditure on cutting balloons in 2022 was USD 154.3 Million.
The United States stands out as a prominent market for cutting balloons in the North American region due to the high prevalence of acute coronary syndrome (ACS) and coronary heart disease (CHD). With CHD accounting for a significant portion of deaths, ACS is a symptomatic form that demands effective treatment.
Consequently, the United States' high incidence of heart disease and chest pain-related emergency visits positions it as a key market for cutting balloon technologies.
Germany occupies a 40.3% value share in Europe in 2022, and expenditure on cutting balloons in 2022 was USD 34.3 Billion.
Despite challenges in coordinating inpatient and outpatient care, there is a recognized need for multidisciplinary approaches, including discharge planning, lifestyle guidance, monitoring, and self-care. To address these complexities, a disease management program is set to be introduced in Germany in 2018, reflecting the country's commitment to enhancing cardiac care and making it an attractive market for cutting balloons.
In 2022, Japan held a dominant global revenue in the East Asian market and contributed around USD 33.8 Million.
Japan's attractiveness as a highly lucrative market for cutting balloons stems from its remarkable longevity achievements.
A significant reduction in cardiovascular disease-related mortality, particularly stroke, has played a pivotal role. The prevalence of small vessel disease (arteriolosclerosis) in Japan aligns with its disease profile, mirrored in certain regions of central Asia and Africa. The decline in high blood pressure rates, coupled with improved emergency care and preventive measures, has driven these health outcomes.
To combat emerging risks like ischemic heart disease, Japan is compelled to pioneer innovative models for cardiovascular disease prevention and control, addressing chronic ailments and promoting overall health.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Market Growth Outlook by Key Products
| Products | Value CAGR |
|---|---|
| Drug-coated Cutting Balloons | 6.0% |
| Conventional Cutting Balloons | 5.4% |
| Scoring Balloons | 5.1% |
By product, drug-coated cutting balloons covered 42.1% of market shares in the world in 2022. The product predicted to rapidly expand between 2023 and 2033 is the Drug-coated balloon (DCB). With the rising prevalence of coronary artery disease (CAD), DCB treatment presents a revolutionary approach.
By delivering anti-proliferative drugs directly to vessel walls, DCB treatment offers advantages like reduced reliance on stents, immediate drug release, and potential reduction in antiplatelet therapy duration. Its applications extend to various coronary diseases, including restenosis, small vessel disease, and chronic occlusion. Multiple trials have validated its efficacy, positioning DCB as an innovative solution for CAD treatment, making it poised for rapid expansion in the coming decade.
Market Growth Outlook by Key Applications
| Application | Value CAGR |
|---|---|
| Coronary Artery Disease | 5.2% |
| Peripheral Artery Disease | 6.2% |
The market value of coronary artery disease in cutting balloons is USD 234.1 Million, representing a sizable 58.5% market share in 2022. Cutting balloons have gained favor as a preferred choice for treating Coronary Artery Disease (CAD) due to their efficacy in addressing atherosclerotic plaque obstruction. CAD, characterized by impaired blood flow and oxygen delivery, contributes significantly to morbidity and mortality.
Cutting balloons mitigates this by utilizing microsurgical blades during balloon inflation, enabling precise plaque modification without extensive vessel trauma. This approach minimizes complications like dissections, enhancing procedural success. Given CAD's global burden and economic impact, cutting balloons offers a tailored solution to restore blood flow, reduce symptoms, and improve patient outcomes, making them a valuable tool in CAD management.
Market Growth Outlook by Key End Users
| End User | Value CAGR |
|---|---|
| Hospitals | 5.8% |
| Cardiac Centers | 5.3% |
| Ambulatory Surgical Centers | 5.6% |
The hospitals have a considerable presence in the cutting balloons market, accounting for 45.8% of end users in 2022, and exhibiting a high CAGR of 5.8% over the forecast period. The key end consumers of the global coronary artery disease market are hospitals. Hospitals are essential healthcare facilities that are crucial in the detection, treatment, and management of coronary artery disease (CAD). They provide a wide range of therapies for CAD patients, such as diagnostic procedures, surgical interventions, and rehabilitation programs.
Modern medical technology, experienced cardiologists, and interdisciplinary teams are all found in hospitals, providing efficient patient care and illness control. Hospitals are crucial recipients of developments and innovations in the worldwide coronary artery disease market because of their central role in the treatment of CAD; this improves patient outcomes and boosts the effectiveness of healthcare as a whole.
Advancements and partnerships within healthcare providers, research institutes, and tech enterprises foster cutting-edge innovation. Collaborative efforts boost market growth and diversify applications. Several prominent companies vie in the cutting balloon sector, including:
Similarly, recent developments related to the company’s manufacturing the cutting balloons have been tracked by the team at Future Market Insights, which are available in the full report.
Related Market Growth Outlook Scenario
| Particulars | Value CAGR |
|---|---|
| Angiography Devices Market | 6.2% |
| Angiographic Catheters Market | 4.3% |
| Peripheral Angioplasty Market | 7.7% |
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value, Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa. |
| Key Market Segments Covered | Product, Application, End User, and Region |
| Key Companies Profiled | Abbott; Boston Scientific Corporation; B. Braun Melsungen AG; Cook Medical; Cordis; Medtronic; MicroPort Scientific Corporation; Opto Circuits (India) Ltd.; Spectranetics (Philips Healthcare); Terumo Corporation; TriReme Medical, LLC (QT Vascular Ltd.); Vascular Concepts Limited |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The global market is worth USD 400.2 Million in 2022.
The global market estimate for 2023 is around USD 421.2 Million.
The global market is expected to reach USD 725.9 Million by the end of 2033
The global market grew at a CAGR of 3.8% between 2017 and 2022.
The United States contributed around USD 154.3 Million in the year 2022.
Germany holds nearly 8.6% market share in the global market in 2022.
Japan accounted for a market value share of around 8.4% in 2022 globally.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Value Added Insights 5. Market Background 6. Global Market Demand (in Volume) Analysis 2017 to 2022 and Forecast, 2023 to 2033 7. Global Market – Pricing Assessment 8. Global Market Demand (in Value or Size in USD Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product 9.1. Drug-coated Cutting Balloons 9.2. Conventional Cutting Balloons 9.3. Scoring Balloons 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application 10.1. Coronary Artery Disease 10.2. Peripheral Artery Disease 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 11.1. Hospitals 11.2. Cardiac Centers 11.3. Ambulatory Surgical Centers 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. South Asia 12.5. East Asia 12.6. Oceania 12.7. Middle East and Africa 13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 20. Market Structure Analysis 21. Competition Analysis 21.1. Abbott 21.2. Boston Scientific Corporation 21.3. B. Braun Melsungen AG 21.4. Cook Medical 21.5. Cordis 21.6. Medtronic 21.7. MicroPort Scientific Corporation 21.8. Opto Circuits (India) Ltd. 21.9. Spectranetics (Philips Healthcare) 21.10. Terumo Corporation 21.11. TriReme Medical, LLC (QT Vascular Ltd.) 21.12. Vascular Concepts Limited 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Cutting Balloons Market
